Search

Your search keyword '"Cereja, Sophie"' showing total 10 results
Start Over Author "Cereja, Sophie" Language english
10 results on '"Cereja, Sophie"'

2. Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma

Author

Bobin, Arthur, Kyheng, Maéva, Guidez, Stéphanie, Gruchet-Merouze, Cécile, Richez, Valentine, Duhamel, Alain, Karlin, Lionel, Kolb, Brigitte, Tiab, Mourad, Araujo, Carla, Meuleman, Nathalie, Malfuson, Jean-Valère, Bourquard, Pascal, Lenain, Pascal, Perrot, Aurore, Roussel, Murielle, Jaccard, Arnaud, Petillon, Marie-Odile, Belhadj-Merzoug, Karim, Chretien, Marie-Lorraine, Fontan, Jean, Rodon, Philippe, Schmitt, Anna, Offner, Fritz, Voillat, Laurent, Cereja, Sophie, Kuhnowski, Frédérique, Rigaudeau, Sophie, Decaux, Olivier, Humbrecht-Kraut, Catherine, Frayfer, Jamile, Fitoussi, Olivier, Roos-Weil, Damien, Eisenmann, Jean Claude, Dorvaux, Véronique, Voog, Eric G., Moreau, Philippe, Avet-Loiseau, Hervé, Hulin, Cyrille, Facon, Thierry, and Leleu, Xavier

Published
2022
Full Text
View/download PDF

4. Evolving Characteristics and Outcome of Secondary Acute Promyelocytic Leukemia (APL): A Prospective Analysis by the French-Belgian-Swiss APL Group

Author

Braun, Thorsten, Cereja, Sophie, Chevret, Sylvie, Raffoux, Emmanuel, Beaumont, Marie, Detourmignies, Laurence, Pigneux, Arnaud, Thomas, Xavier, Bordessoule, Dominique, Guerci, Agnès, Lamy, Thierry, Recher, Christian, Poiré, Xavier, Tournilhac, Olivier, Spertini, Olivier, Chomienne, Christine, Degos, Laurent, Dombret, Hervé, Adès, Lionel, and Fenaux, Pierre

Published
2015
Full Text
View/download PDF

5. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases

Author

Kiladjian, Jean-Jacques, Cervantes, Francisco, Leebeek, Franck W.G., Marzac, Christophe, Cassinat, Bruno, Chevret, Sylvie, Cazals-Hatem, Dominique, Plessier, Aurélie, Garcia-Pagan, Juan-Carlos, Murad, Sarwa Darwish, Raffa, Sebastian, Janssen, Harry L.A., Gardin, Claude, Cereja, Sophie, Tonetti, Carole, Giraudier, Stéphane, Condat, Bertrand, Casadevall, Nicole, Fenaux, Pierre, and Valla, Dominique C.

Published
2008
Full Text
View/download PDF

6. Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03) / 57th Annual Meeting of the American-Society-of-Hematology - Orlando, FL

Author

Leleu, Xavier, Karlin, Lionel, Kolb, Brigitte, Tiab, Mourad, Araujo, Carla, Meuleman, Nathalie, De Revel, Thierry, Bourquard, Pascal, Lenain, Pascal, Roussel, Murielle, Jaccard, Arnaud, Petillon, Marie-Odile, Belhadj-Merzoug, Karim, Lepeu, Gerard, Chretien, Marie-Lorraine, Fontan, Jean, Rodon, Philippe, Schmitt, Anna, Offner, Fritz, Voillat, Laurent, Cereja, Sophie, Kuhnowski, Frederique, Rigaudeau, Sophie, Decaux, Olivier, Humbrecht-Kraut, Catherine, Frayfer, Jamile, Fitoussi, Olivier, Weil, Damien Roos, Eisenmann, Jean Claude, Dorvaux, Véronique, Voog, Eric G., Hulin, Cyrille, Attal, Michel, Moreau, Philippe, Facon, Thierry, Service d'Hématologie, Centre Hospitalier Universitaire de Reims (CHU Reims), Hôpital Général de La Roche sur Yon, Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), CHU Pontchaillou [Rennes], Service d'Hématologie clinique et thérapie cellulaire [CHU Limoges], CHU Limoges, Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Henri Duffaut (Avignon), Lipides - Nutrition - Cancer (U866) (LNC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bourgogne (UB)-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Service d'hématologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Chalon-sur-Saône William Morey, Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier de Meaux, Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Laboratoire d'Hématologie [Rangueil], Hôpital de Rangueil, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Service d'Hématologie Clinique, Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Claude Huriez [Lille], CHU Lille, Jonchère, Laurent, Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service Hématologie - IUCT-Oncopole [CHU Toulouse], Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle IUCT [CHU Toulouse], and Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio]
Abstract

WOS:000368020103223; International audience; Conference: 57th Annual Meeting of the American-Society-of-Hematology - Orlando, FL - DEC 05-08, 2015

Published
2015

7. Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03)

Author

Leleu, Xavier, Fouquet, Guillemette, Karlin, Lionel, Kolb, Brigitte, Tiab, Mourad, Araujo, Carla, Bourquard, Pascal, Lenain, Pascal, Roussel, Muriel, Jaccard, Arnaud, Petillon, Marie-Odile, Belhadj-Merzoug, Karim, Lepeu, Gérard, Chretien, Marie-Lorraine, Fontan, Jean, Rodon, Philippe, Schmitt, Anna, Voillat, Laurent, Cereja, Sophie, Kuhnowski, Frédérique, Rigaudeau, Sophie, Decaux, Olivier, Frayfer, Jamile, Fitoussi, Olivier, Roos Weil, Damien, Eisenmann, Jean-Claude, Dorvaux, Véronique, Voog, Eric, Hulin, Cyrille, and Attal, Michel

Published
2017
Full Text
View/download PDF

9. Posterior reversible encephalopathy syndrome (PRES) and myeloma.

Author

Ghanem R, Glaisner S, Bobin A, Ronchetti AM, Cereja S, Joly B, Salanoubat C, and Fouquet G

Abstract

Posterior reversible encephalopathy syndrome (PRES) has rarely been described in myeloma, but chemotherapy is a known risk factor. We report 3 patients with myeloma who developed PRES, and analyzed them with 13 published cases, mostly women. The most frequent causative agents were proteasome inhibitors and autologous stem cell transplantation. Risk factors were frequently associated: hypertension, infection or renal failure. Symptoms included headache, blurred vision, altered mental status, seizures. Most patients experienced rapid clinical recovery, without relapse even after resuming treatment. Although rare, we must remain vigilant about PRES in myeloma patients. Stricter control of blood pressure could limit its occurrence., Competing Interests: The authors have no conflict of interest related to this manuscript., (© 2024 The Authors. Published by Elsevier Ltd.)

Published
2023
Full Text
View/download PDF

10. Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.

Author

Leleu X, Fouquet G, Richez V, Guidez S, Duhamel A, Machuron F, Karlin L, Kolb B, Tiab M, Araujo C, Meuleman N, Malfuson JV, Bourquard P, Lenain P, Roussel M, Jaccard A, Pétillon MO, Belhadj-Merzoug K, Lepeu G, Chrétien ML, Fontan J, Rodon P, Schmitt A, Offner F, Voillat L, Cereja S, Kuhnowski F, Rigaudeau S, Decaux O, Humbrecht-Kraut C, Frayfer J, Fitoussi O, Roos-Weil D, Eisenmann JC, Dorvaux V, Voog EG, Attal M, Moreau P, Avet-Loiseau H, Hulin C, and Facon T

Subjects
Aged, Aged, 80 and over, Drug Administration Schedule, Female, Hematopoietic Stem Cell Transplantation methods, Humans, Male, Maximum Tolerated Dose, Melphalan administration & dosage, Multiple Myeloma pathology, Oligopeptides administration & dosage, Patient Safety, Prednisone administration & dosage, Response Evaluation Criteria in Solid Tumors, Survival Rate, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Multiple Myeloma drug therapy
Abstract

Purpose: Carfilzomib is a novel generation proteasome inhibitor. The Carmysap trial demonstrated that twice-weekly KMP (carfilzomib, melphalan, prednisone) might challenge the MPV (melphalan, prednisone, bortezomib) standard. We sought to study KMP weekly, allowing to increase carfilzomib's dose with maintained efficacy and improved safety profile., Patients and Methods: IFM2012-03, a phase I multicenter study of KMP weekly in elderly patients with newly diagnosed multiple myeloma (eNDMM), aimed to determine the MTD of carfilzomib. Carfilzomib was given intravenously at 36, 45, 56, and 70 mg/m 2 /day on days 1, 8, 15, and 22 with melphalan and prednisone, for nine 35-day induction cycles, followed by carfilzomib maintenance for 1 year. Three dose-limiting toxicities (DLT) determined MTD at the lower dose., Results: Thirty eNDMMs were treated, 6 per cohort at 36, 45, and 56 mg/m 2 and 12 at 70 mg/m². There was one DLT at 36 mg/m 2 (lymphopenia), one at 45 mg/m 2 (lysis syndrome), two at 56 mg/m 2 (cardiac insufficiency and febrile neutropenia), and two at 70 mg/m 2 (vomiting and elevated liver enzymes). The safety profile was acceptable; however, specific attention must be paid to the risk of cardiovascular events, especially for elderly patients. The overall response rate was 93.3%, with 46.6% complete response., Conclusions: The MTD dose of carfilzomib was 70 mg/m 2 in this KMP weekly study in eNDMM. Response rates, and especially CR rate, were remarkable in this population, and would benefit from being assessed in a larger-scale study. The IFM2012-03 study demonstrated that the MTD of carfilzomib weekly is 70 mg/m 2 in eNDMM, and 56 mg/m 2 for patients older than 75 years. Carfilzomib used weekly in combination has a good efficacy and safety profile in eNDMM., (©2019 American Association for Cancer Research.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results